Clinical Trials Logo

Neuroendocrine Neoplasm of Lung clinical trials

View clinical trials related to Neuroendocrine Neoplasm of Lung.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03095274 Completed - Clinical trials for Neuroendocrine Tumors

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

DUNE
Start date: April 11, 2017
Phase: Phase 2
Study type: Interventional

Well-differentiated gastroenteropancreatic and lung neuroendocrine tumors are generally malignancies with a prolonged natural history. However, clinical behavior is heterogeneous and when tumor progression is observed, treatment options are limited. The most used therapy for neuroendocrine tumors management are somatostatin analogs. However, even the use in lung carcinoids is quite usual, no antitumoral activity has been demonstrated. Tremelimumab and Durvalumab combination could be more efficient drugs to improve immune system activation and could obtain a significantly higher clinical benefit in these patients. Tremelimumab and Durvalumab would be the first immune combination agents showing efficacy in neuroendocrine neoplasms of different origins.